This explains why some enzyme producers such as Novozymes are investing more and more in the development of this field
Paris (PRWEB) July 8, 2008
According to CBDM.T®, The market and business intelligence company, the enzyme market is significant and estimated at € 3.4 billion with an annual growth of about 6.5 to 10%. Products such as Maltogenase (amylase) and Lipolase (lipase) were first biotech enzymes marketed in the 80's. While enzymes are present everywhere and come in thousands of different forms, there are still only about 25 of them which have actually been industrialised and commercialised. They include Amylase, Protease, Lipase, Cellulase, Glycomylase, Glucose Isomerase, Chymosin, Lactase, Pullulanase and Xylanase.
Some countries have a better developed enzyme industry than others, so descriptions of these countries and the nature of the environment they provide for upcoming businesses is given in this market review. In some countries, the industry was developed with support from the state from as early as the 1980's. These are countries such as Denmark, USA and Brazil. The real breakthrough in the industry happened during the 1970s. A new technology was developed, recombinant biotechnology, and this permitted biochemists to create and modify molecules at an unprecedented level.
Enzymes are sold in many different industry segments. These segments are Detergents, Food, Feed, Technical, Pharmaceutical, Microorganisms and Biofuel. For example in the feed industry, enzymes help pigs or chickens digest their food better, which in the end helps producing better meat, while using smaller amounts of fodder. These segments are thoroughly described in this enzyme market review, looking at market sizes, growth and, while looking at global and key market drivers for each segment are also identified and analyzed.
Biofuel is dealt with in particular depth, since it is a potentially large segment for the future. The global Biofuel market (biodiesel derived from vegetable oil and ethanol derived from sugar or starch) was estimated to be worth €25 billion in 2007.
Biocatalysis is also more frequently applied by chemical companies, since it is the pertinent technology for the manufacturing of chiral drugs and sometimes for oil-based chemistry substitution. Enzymes are a key element in performing biocatalysis (biocatalysts are in fact enzymes). This means that biocatalysis will probably be a significant segment in the future enzyme market. This promising market segment is difficult to estimate. But we know that this market segment will affect the market of catalysts estimated by CBDM.T® at more than $7 billion."This explains why some enzyme producers such as Novozymes are investing more and more in the development of this field" says Philippe Tramoy, managing partner.
Key players are: Novozymes, Danisco, Genencor, Verenium, Syngenta, Monsanto, Dyadic, Codexis, Cargill, Diversa, ADM, Dow, IEP, DSM, Genzyme, BASF, Altus, Biocon, Henkel, Roche, Sanofi, Solvay, Direvo, Maxygen...
If you need more information about CBDM.T® Enzyme Market Review, please contact us at contact @ cbdmt.com.
CBDM.T® - Market and Business Intelligence - is a market and business intelligence company with offices in France and in Israel. As an advisory services company, CBDM.T® boosts companies to develop revenue and growth by providing business and marketing services in the life science and biotech markets (market survey, market scouting, business development and strategic supports).
For more information:
CBDM.T® Market and Business Intelligence
88-90 rue de la Mare
Fr-75020 Paris - France
Tel : +33 1 4474 7957
Email : contact @ cbdmt.com
Web site : CBDM.T®
CBDM.T® - Israel
Netanya - 42490 - Israel
Tel: +972 52 3316190